Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PANACEA LIFE SCIENCES HOLDINGS, INC.EXDI · Entity 9699 | CHIEF GROWTH OFFICER | January 22, 2021 | February 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PANACEA LIFE SCIENCES HOLDINGS, INC.
Report date January 22, 2021 · Filed February 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,792,490 |
Reported balance
After 2021-01-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-01-22 · Grant · Acquired 8,186,240 · Balance 12,792,490 F1: The reporting person was issued a total of 8,186,240 shares of common stock in payment of accrued compensation, reimbursable expenses, and loans advanced to the company. F2: Consists of 8,498,740 shares of common stock, together with: (i) options to purchase 31,250 shares of common stock at a price of $0.96 per share, exercisable until 1/15/29; (ii) options to purchase 12,500 shares of common stock at a price of $0.32 per share, exercisable until 1/15/29; (iii) options to purchase 750,000 shares of common stock at a price of $0.32 per share, exercisable until 3/12/29; and (iv) options to purchase 3,500,00 shares of common stock at a price of $0.025 per share, exercisable until 1/22/23. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2023-01-22 | Direct | 3,500,000 |
Reported balance
After 2021-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-22 · Grant · Acquired 3,500,000 · Balance 3,500,000 F3: The reporting person was granted two year options to purchase 3,500,000 shares of Common Stock at an exercise price of $0.025 per share. Provided Mr. Johnson has not resigned or been removed prior to vesting, fifty (50%) percent of such amount shall vest upon issuance and fifty (50%) percent upon the closing of any acquisition with a combined value (target and the Corporation) in excess of five million ($5,000,000) dollars. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was issued a total of 8,186,240 shares of common stock in payment of accrued compensation, reimbursable expenses, and loans advanced to the company.
F2: Consists of 8,498,740 shares of common stock, together with: (i) options to purchase 31,250 shares of common stock at a price of $0.96 per share, exercisable until 1/15/29; (ii) options to purchase 12,500 shares of common stock at a price of $0.32 per share, exercisable until 1/15/29; (iii) options to purchase 750,000 shares of common stock at a price of $0.32 per share, exercisable until 3/12/29; and (iv) options to purchase 3,500,00 shares of common stock at a price of $0.025 per share, exercisable until 1/22/23.
F3: The reporting person was granted two year options to purchase 3,500,000 shares of Common Stock at an exercise price of $0.025 per share. Provided Mr. Johnson has not resigned or been removed prior to vesting, fifty (50%) percent of such amount shall vest upon issuance and fifty (50%) percent upon the closing of any acquisition with a combined value (target and the Corporation) in excess of five million ($5,000,000) dollars.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2021 Filed Feb 2, 2021 18:56 UTC | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | GrantOptions to purchase common stock · Derivative | 3,500,000 | $0.03 Strike: $0.03 | $87,500.00 |
DisclosureSEC source: 0001415889-21-000478 · form4-02022021_100200.xml · derivative · entry 2 Johnson Andrew L. · CIK 0001773143 · CHIEF GROWTH OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500,000 Underlying: Common stock · 3,500,000 shares Expires 2023-01-22 F3 · derivative.exercise_date: The reporting person was granted two year options to purchase 3,500,000 shares of Common Stock at an exercise price of $0.025 per share. Provided Mr. Johnson has not resigned or been removed prior to vesting, fifty (50%) percent of such amount shall vest upon issuance and fifty (50%) percent upon the closing of any acquisition with a combined value (target and the Corporation) in excess of five million ($5,000,000) dollars. Read SEC document |
| January 22, 2021 Filed Feb 2, 2021 18:56 UTC | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | GrantCommon Stock | 8,186,240 | $0.03 | $204,656.00 |
DisclosureSEC source: 0001415889-21-000478 · form4-02022021_100200.xml · nonDerivative · entry 1 Johnson Andrew L. · CIK 0001773143 · CHIEF GROWTH OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,792,490 F1 · price: The reporting person was issued a total of 8,186,240 shares of common stock in payment of accrued compensation, reimbursable expenses, and loans advanced to the company. F2 · balance_after: Consists of 8,498,740 shares of common stock, together with: (i) options to purchase 31,250 shares of common stock at a price of $0.96 per share, exercisable until 1/15/29; (ii) options to purchase 12,500 shares of common stock at a price of $0.32 per share, exercisable until 1/15/29; (iii) options to purchase 750,000 shares of common stock at a price of $0.32 per share, exercisable until 3/12/29; and (iv) options to purchase 3,500,00 shares of common stock at a price of $0.025 per share, exercisable until 1/22/23. Read SEC document |
| February 01, 2020 Filed Feb 6, 2020 20:08 UTC | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000288 · form4-02062020_120200.xml · nonDerivative · entry 1 Johnson Andrew L. · CIK 0001773143 · CHIEF STRATEGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,106,250 F1 · balance_after: Consists of 312,500 shares of common stock, together with: (i) options to purchase 31,250 shares of common stock at a price of $0.96 per share, exercisable until 1/15/29; (ii) options to purchase 12,500 shares of common stock at a price of $0.32 per share, exercisable until 1/15/29; and (iii) options to purchase 750,000 shares of common stock at a price of $0.32 per share, exercisable until 3/12/29 Read SEC document |
| December 18, 2019 Filed Dec 19, 2019 21:37 UTC | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | PurchaseCommon Stock | 62,500 | $0.40 | $25,000.00 |
DisclosureSEC source: 0001415889-19-001542 · form4-12192019_011208.xml · nonDerivative · entry 1 Johnson Andrew L. · CIK 0001773143 · CHIEF STRATEGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,250 F1 · balance_after: Consists of 62,500 shares of common stock as reported herein, together with: (i) options to purchase 31,250 shares shares of common stock at a price of $0.96 per share, exercisable until 1/15/29; (ii) options to purchase 12,500 shares of common stock at a price of $0.32 per share, exercisable until 1/15/29; and (iii) options to purchase 750,000 shares of common stock at a price of $0.32 per share, exercisable until 3/12/29 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.